louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05876520: Clinical and Radiographic Assessment of Nano-Bioactive Glass Combined With I-PRF Scaffold in Vital Pulp Treatments in Mandibular Molars With Closed Apices
Official title: Clinical and Radiographic Assessment of Nano-Bioactive Glass Combined With I-PRF Scaffold in Vital Pulp Treatments in Mandibular Molars With Closed Apices: A Triple Blinded "Randomized Controlled Trial"
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Vital Pulp Treatment in Mature Permanent Teeth With Irreversible Pulpitis
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2023-05-25
Enrollment: 28
Sex: ALL
Minimum age (years): 14
Maximum age (years): 32
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: Total Pulpotomy in mature permanent teeth treated with Nano-bioactive glass mixed with I-PRF
Primary purpose: TREATMENT

Brief summary: Clinical, Radiographic and pain assessment of Vital pulp treatment in patients suffering from irreversible pulpitis in mature permanent molars. Total pulpotomy is investigated using I-prf only vs I-prf mixed with Nano-bioactive glass.


Eligibility criteria: Inclusion Criteria:

* Patients suffering from Symptomatic irreversible pulpitis in mature mandibular molars only will be involved.
* Tooth should give positive response to cold test
* Haemostasias should be achieved after total pulpotomy
* The tooth is restorable and free from advanced periodontal disease, cracks and splits.
* Patients should be free from any systemic disease that may affect normal healing and predictable outcome.
* Patients who will agree to the consent and will commit to follow-up period.
* Patients with mature root apices
* Patients with no internal or external resorption and no periapical lesions
* Soft tissues around the tooth are normal with no swelling or sinus tract.

Exclusion Criteria:

* Patients with immature roots.
* Haemostasias after 10 minutes can not be controlled after total pulpotomy
* Patients with any systemic disease that may affect normal healing.
* Patients with periapical lesions or infections.
* Pregnant females.
* Patients who could/would not participate in a 6 months follow-up.
* Patients with fistula or swelling
* Patients with necrotic pulp.
* Patients with old age.

Primary outcomes:
measure: Clinical , Radiographic and Success rate
timeFrame: 6 month follow up
Secondary outcomes:
measure: Pain intensity
timeFrame: Within the first 24 hrs upto the 7th day
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Noor Mohammed Kamal Eldeen
Study officials:
affiliation: Vice Dean of Faculty of Dentistry Cairo University
name: Geraldine Ahmed
role: STUDY_DIRECTOR
affiliation: Lecturer of Endodontics
name: Ahmed S. Elsheshtawy
role: STUDY_CHAIR
affiliation: Lecturer of Biomaterials
name: Ayah Abdolwahab
role: STUDY_CHAIR
affiliation: Resident of Endodontics
name: Noor K. Sayed
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05168020: Evaluation of a Self-Monitoring Intervention to Reduce Safety Behavior in Social Anxiety
Official title: Evaluation of a Self-Monitoring Intervention to Reduce Safety Behaviors in Social Anxiety: A Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Social Anxiety
Keywords: Social Anxiety
Safety Behaviors
Intervention
Text-message
Lead sponsor: Florida State University
Sponsor class: OTHER
First posted: 2021-12-22
Enrollment: 154
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Participants are randomized in to one of two conditions
Primary purpose: TREATMENT

Brief summary: The current study aims to explore the efficacy of a text message based Safety Behavior Fading Intervention compared to an active control intervention.

Detailed description: Safety behavior fading may be a viable standalone intervention for social anxiety. In the present trial, participants high in social anxiety will be randomized to either receive a daily checklist exercise aimed at eliminating (1) safety behaviors or (2) unhealthy behaviors. Individuals randomly assigned to the safety behavior fading condition will receive instructions to decrease or eliminate their four most habitual social anxiety safety behaviors. In addition, they will receive daily reminders via text message to decrease these behaviors, along with a safety behavior monitoring checklist in which the participant indicates the extent to which they decreased and/or eliminated each safety behavior over the previous day. Individuals randomly assigned to the control condition will receive similar text messages and a daily checklist to encourage fading of unhealthy behaviors. Participants in both conditions will complete checklists for 28 days. After day 14 of treatment, participants will re-select their target safety behaviors or unhealthy behaviors, and will then be prompted to reduce these new behaviors for another 14 days.

Eligibility criteria: Inclusion Criteria:

* Social Phobia Inventory Score \>29
* Stable Psychotropic Medications for 4 weeks prior to participation

Exclusion Criteria:

* Currently participating in psychotherapy

Primary outcomes:
measure: Change in Social Phobia Inventory Score
timeFrame: Day 0, Day 14, Day 42
Secondary outcomes:
Other outcomes:
Locations:
city: Tallahassee
country: United States
facility: Florida State University
state: Florida
Study officials:
References:
Clinical trial NCT06426420: Endometriosis and ATR-FTIR Spectroscopy
Official title: Detection of Endometriosis Using ATR-FTIR Spectroscopy
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Endometriosis
Endometriomas
Keywords: Endometriosis
Diagnosis
Spectroscopy
FTIR
Urine
Detection
Infrared
Lead sponsor: Federal University of Espirito Santo
Sponsor class: OTHER
Collaborators: name: Conselho Nacional de Desenvolvimento Científico e Tecnológico
First posted: 2024-05-23
Enrollment: 600
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: The goal of this study is to explore the use of mid-infrared spectroscopy (ATR-FTIR) as a detection tool for endometriosis in urine.

Detailed description: Endometriosis is a chronic gynecological disease that is considered debilitating and multifactorial. Its diagnosis is invasive and can be prolonged due to non-specific symptoms and erroneous or late investigations, which can lead to delays and impair the provision of adequate treatment.

ATR-FTIR Spectroscopy is a non-invasive technique with the capability to identify the chemical composition and molecular changes of samples through its interaction with mid-infrared radiation. The aim of this work is to develop a rapid test for the detection of endometriosis in urine samples using spectroscopy and machine learning algorithms.

Eligibility criteria: Inclusion Criteria:

* Female
* Pelvic pain complain

Exclusion Criteria:

* Age under 18 or above 55
* Lack of informed consent

Primary outcomes:
measure: Spectroscopy Reliability (diagnostic metrics)
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Vitória
country: Brazil
facility: University Hospital Cassiano Antonio Moraes at Federal Univeristy Of Espírito Santo
state: Espírito Santo
Study officials:
affiliation: Universidade Federal do Espírito Santo
name: Valerio G Barauna, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04727320: The Clinical Application of Tauroursodeoxycholic Acid in Patients With Liver Fibrosis.
Official title: The Clinical Application of Tauroursodeoxycholic Acid in Patients With Liver Fibrosis.
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: EARLY_PHASE1
Conditions: Liver Cirrhosis
Lead sponsor: The First Affiliated Hospital with Nanjing Medical University
Sponsor class: OTHER
First posted: 2021-01-27
Enrollment: 60
Sex: ALL
Minimum age (years): 30
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study is a prospective study. We signed an informed consent form with patients with liver fibrosis and took tauroursodeoxycholic acid orally for half a year. After half a year, liver biopsy was performed using histopathology, immunohistochemistry, and polymerase chain reaction, Western blotting method was used to determine the expression level of fibrosis-related markers to verify the effect of taurodeoxycholic acid on patients with liver fibrosis.

Detailed description: Tauroursodeoxycholic acid is an effective component of bear bile, which has obvious curative effects in the treatment of gallstones and liver diseases. In recent years, the research field of tauroursodeoxycholic acid has been very active, and its chemical synthesis has also attracted much attention. The usage is swallowing with water before going to bed at night. It must be taken regularly, one capsule at a time (250mg), once a day. After 6 months of continuous use, liver biopsy was performed after 6 months. Telling the patient to swallow with water before going to bed at night. It must be taken regularly, one capsule at a time (250mg), once a day. After 6 months of continuous use, liver B-ultrasound biopsy was performed to observe the effect.

Eligibility criteria: Inclusion Criteria:

* Clinical diagnosis of liver cirrhosis and liver fibrosis in patients requiring medical treatment.

Exclusion Criteria:

* Patients with end-stage cirrhosis, liver failure, etc. who need liver transplantation.

Primary outcomes:
measure: Liver biopsy
timeFrame: up to 24 weeks
Secondary outcomes:
measure: Liver ultrasound
timeFrame: up to 24 weeks
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00000220: Gradual Vs. Rapid Buprenorphine Detoxification - 2
Official title: Gradual Vs. Rapid Buprenorphine Detoxification
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Opioid-Related Disorders
Lead sponsor: National Institute on Drug Abuse (NIDA)
Sponsor class: NIH
Collaborators: name: University of Vermont
First posted: 1999-09-21
Enrollment: 0
Sex: ALL
Minimum age (years): 33
Maximum age (years): 43
Standard ages: ADULT
Accepts healthy volunteers: no
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine an optimal detoxification dose reduction schedule with buprenorphine.


Eligibility criteria: Please contact site for information.

Primary outcomes:
measure: Drug use
measure: Retention
measure: Observed withdrawal rating
measure: Opioid agonist rating
measure: Opioid antagonist rating
Secondary outcomes:
Other outcomes:
Locations:
city: Burlington
country: United States
facility: Treatment Research Center
state: Vermont
Study officials:
affiliation: University of Vermont
name: Warren Bickel, Ph.D.
role: PRINCIPAL_INVESTIGATOR
References:
citation: Amass L, Bickel WK, Higgins ST, Hughes JR. A preliminary investigation of outcome following gradual or rapid buprenorphine detoxification. J Addict Dis. 1994;13(3):33-45. doi: 10.1300/j069v13n03_04.
Clinical trial NCT03678220: Assessment of Augmented Reality in Minimally Invasive Surgery
Official title: Clinical Translation of Augmented Reality Visualization for Laparoscopic Surgery
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Laparoscopic Hepatectomy
Laparoscopic Liver Thermal Ablation
Keywords: Laparoscopic Ultrasound
Lead sponsor: IGI Technologies, Inc.
Sponsor class: INDUSTRY
Collaborators: name: National Institutes of Health (NIH)
name: National Cancer Institute (NCI)
name: University of Pittsburgh Medical Center
First posted: 2018-09-19
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: SUPPORTIVE_CARE

Brief summary: The objective of this study is to test the technical feasibility of LapAR visualization system for guiding laparoscopic surgeries and to gather clinical feedback on the use of this tool.

Detailed description: Surgeons use real-time video generated by a laparoscope to visualize the operative field when performing laparoscopic procedures. An inability to see beneath organ surfaces is a limitation of the current visualization technology. Surgeons additionally use laparoscopic ultrasound to see beneath organ surfaces, but also need to mentally correlate the ultrasound image with the video of the operative field. This process is difficult, subjective, and variable with expertise, and discourages the use of ultrasound.

The investigators have developed a method to combine live laparoscopic video and laparoscopic ultrasound images to present fused multimodality images on a single display, eliminating the need for mental image correlation. Specifically, the image fusion method, called laparoscopic augmented reality (LapAR), augments the laparoscopic video with ultrasound data when required by surgeons. This study is designed to test this minimal-risk capability in patients referred for relevant laparoscopic procedures.

Eligibility criteria: Inclusion Criteria:

1. Patient is referred for either laparoscopic partial hepatectomy for tumor removal or laparoscopic ablation of liver cancer;
2. Patient must be at least 18 years old;
3. Patient provides written consent;
4. Patient is considered a suitable candidate based on tumor location for using the AR system.

Exclusion Criteria:

Patients with pacemaker or any other ICD(intra-cardiac device) which may interfere with electromagnetic tracking

Primary outcomes:
measure: Surgeon interview regarding usability
timeFrame: post surgery, an expected average of 5 minutes
measure: Procedure time
timeFrame: during surgery
measure: Measurement of margin
timeFrame: post surgery
Secondary outcomes:
measure: System set-up time
timeFrame: before surgery, an expected average of 15 min
Other outcomes:
Locations:
city: Pittsburgh
country: United States
facility: University of Pittsburgh Medical Center
state: Pennsylvania
Study officials:
References:
Clinical trial NCT03966820: Subjective Ageing in Fibromyalgia
Official title: Subjective Ageing in Fibromyalgia: Why Fibromyalgia Patients Feel Old?
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Fibromyalgia
Keywords: Anxiety
Cognitive ageing
Depression
Fatigue
Fibromyalgia
Quality of life
Sleep
Lead sponsor: Gaziosmanpasa Research and Education Hospital
Sponsor class: OTHER_GOV
First posted: 2019-05-29
Enrollment: 262
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: 262 patients diagnosed with fibromyalgia will be included in the study

Brief summary: Subjective age or felt age is the term used for how the person feels; one can feel same, younger or older than their actual age. Feeling younger or feeling older may be associated with depression, anxiety, fatigue, sleep, quality of life or cognitive function.

Detailed description: In this cross-sectional study, the investigators hypothesized that fibromyalgia patients mostly feel older than their actual age and this felt age may be associated with depression, anxiety, fatigue, sleep, quality of life or cognition. After power analysis, study sample calculated as 262 patients, the present study will use 2016 revised American College of Rheumatology criteria to diagnose fibromyalgia.

Eligibility criteria: Inclusion Criteria:

* Fibromyalgia diagnosis using 2016 revised American College of Rheumatology
* aged \>18 years old
* Widespread pain more than 3 months

Exclusion Criteria:

* Any disease that can cause depression, anxiety, fatigue, poor sleep quality or poor cognitive function except from fibromyalgia.

Primary outcomes:
measure: Subjective age
timeFrame: Four months
measure: Depression
timeFrame: Four months
measure: Anxiety
timeFrame: Four months
measure: Sleep
timeFrame: Four months
measure: Fatigue
timeFrame: Four months
measure: Cognitive Function
timeFrame: Four months
measure: Life Quailty
timeFrame: Four months
Secondary outcomes:
Other outcomes:
Locations:
city: İstanbul
country: Turkey
facility: Mehmet Akif Guler
state: İ̇stanbul
Study officials:
References:
Clinical trial NCT00871520: Prognosis and Survival Estimates in Palliative Therapy
Official title: Prognosis in Palliative Therapy - a Prospective Study on Survival Prognostication in Advanced Stage Cancer Patients
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Cancer
Keywords: Palliative Care
Predictive Value of Tests
Prospective Studies
Survival Analysis
Survival prediction
Lead sponsor: Heinrich-Heine University, Duesseldorf
Sponsor class: OTHER
First posted: 2009-03-30
Enrollment: 612
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Consecutive unselected cancer patients referred for palliative treatment to one of the participating institutions.

Brief summary: The accuracy of clinical survival estimates is tested in comparison to objective prognostic scores.

Detailed description: * At presentation a clinical survival estimate is obtained in each patient.
* Survival is also estimated using published prognostic scores in palliative care.
* Prognostic scores based on blood samples, general symptoms, complaints, and performance status are calculated and validated, respectively
* Each patient completes questionnaires on psychological distress
* Survival estimates are limited to 6 months.
* Each patient is followed for at least 6 months.

Eligibility criteria: Inclusion Criteria:

* oncologic disease confirmed
* incurable locally advanced or metastatic disease
* palliative treatment intended
* age \> 18
* able to understand the study protocol
* able to complete the forms with assistance if necessary

Exclusion Criteria:

* therapy with curative intent
* regular clinical follow-up visit without disease progression
* ongoing therapy

Primary outcomes:
measure: Survival
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Duesseldorf
country: Germany
facility: University Hospital Duesseldorf, Radiation Oncology Dept.
state: NRW
city: Duesseldorf
country: Germany
facility: Sana Kliniken Duesseldorf Benrath
state: NRW
city: Duesseldorf
country: Germany
facility: Sana Kliniken Duesseldorf Gerresheim, MVZ Onkologie
state: NRW
Study officials:
affiliation: Universtity Hospital Duesseldorf, Radiation Oncology Department
name: Stephan Gripp, Dr.
role: PRINCIPAL_INVESTIGATOR
References:
citation: Gripp S, Moeller S, Bolke E, Schmitt G, Matuschek C, Asgari S, Asgharzadeh F, Roth S, Budach W, Franz M, Willers R. Survival prediction in terminally ill cancer patients by clinical estimates, laboratory tests, and self-rated anxiety and depression. J Clin Oncol. 2007 Aug 1;25(22):3313-20. doi: 10.1200/JCO.2006.10.5411.
Clinical trial NCT01470820: Dose-response Relationship of Phototherapy for Hyperbilirubinaemia Using Diodes: is There a "Saturation Point"
Official title: Dose-response Relationship of Phototherapy for Hyperbilirubinaemia Using Diodes: is There a "Saturation Point"?
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Neonatal Hyperbilirubinemia
Keywords: Neonates
Hyperbilirubinemia
Phototherapy
Light irradiance
Saturation point
Lead sponsor: University of Aarhus
Sponsor class: OTHER
Collaborators: name: Aarhus University Hospital
First posted: 2011-11-11
Enrollment: 151
Sex: ALL
Minimum age (years): 33
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: Background: Using light emitting diodes (LED's) during conventional phototherapy it is possible to reduce the distance from light source to infant, thereby increasing light irradiance.

Objective: To examine the relation between light irradiance and the rate of decrease in total serum bilirubin concentration (TsB) and to see if the investigators can identify a "saturation point", i.e. an irradiation level above which there is no further decrease in TsB.

Design: Prospective randomised study. Setting: Neonatal Intensive Care Unit, Pediatric Department, Aalborg Hospital, Aarhus University Hospital, Denmark.

Material and method: 151 infants with gestational age ≥ 33 weeks and uncomplicated hyperbilirubinaemia are randomised to one of 4 different distances from phototherapy device to mattress (20, 29, 38 and 47 cm). TsB is measured before and after 24 hours of phototherapy and irradiance every 8th hour. Main outcome measure is 24 hours decrease of TsB expressed in percent (∆ TsB0-24 (%)).


Eligibility criteria: Inclusion Criteria:

* Gestational age ≥ 33 weeks
* Uncomplicated neonatal hyperbilirubinemia

Exclusion Criteria:

* \< 33 weeks
* infants in incubators

Primary outcomes:
measure: 24 hours decrease of TsB expressed in percent.
timeFrame: Baseline and 24 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Aalborg
country: Denmark
facility: Pediatric Department, Aalborg Sygehus, Aarhus University Hospital
Study officials:
affiliation: Pediatric department, Aalborg Sygehus, Aarhus University Hospital
name: Pernille K Vandborg, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Pediatric department, Aalborg Sygehus, Aarhus University Hospital
name: Finn Ebbesen, Professor
role: PRINCIPAL_INVESTIGATOR
References:
citation: Vandborg PK, Hansen BM, Greisen G, Ebbesen F. Dose-response relationship of phototherapy for hyperbilirubinemia. Pediatrics. 2012 Aug;130(2):e352-7. doi: 10.1542/peds.2011-3235. Epub 2012 Jul 16.